International
The Morning Science

What science found today

‹
 

Research

Tau Therapy Shows Continued Benefit at 2 Years in Alzheimer's

MedPage Today ·

Tau Therapy Shows Continued Benefit at 2 Years in Alzheimer's

The Brief

  • Diranersen, an investigational antisense oligonucleotide that targets tau, continued to show benefits for 96 weeks.
  • The data come from the open-label extension of the phase II CELIA trial.
  • The results were reported in meeting coverage from CTAD.

Why it matters

It is early open-label extension data from a phase II trial, so it suggests a tau-targeting approach may be worth further study but does not establish efficacy. Science readers can use it to track whether tau-lowering therapies hold up in later, controlled trials.

Who’s affected

  • Alzheimer's disease researchers
  • clinicians and patients following Alzheimer's treatments

(MedPage Today) -- Diranersen, an investigational antisense oligonucleotide therapy that targets tau, continued to show benefits for 96 weeks, data from the open-label extension of the phase II CELIA trial suggested. At 2 years, diranersen continued...

How do you feel about this?

0 Comments

    Tau Therapy Shows Continued Benefit at 2 Years in Alzheimer's – The Morning Science